Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
July 25, 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
June 12, 2019 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
May 02, 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
May 01, 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
April 29, 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
March 04, 2019 16:18 ET
|
Otonomy, Inc.
OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase 1/2 trial in hearing...
Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update
February 25, 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 08, 2018 16:22 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial...
Otonomy Provides Corporate and Product Pipeline Update
January 09, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear,...
Otonomy to Present at Piper Jaffray Healthcare Conference
November 22, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...